---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-082520"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:03:18.667076+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenon files $400M ATM equity prospectus supplement; $291M already sold under prior program

## Summary
- Filed prospectus supplement to register up to $400M of common shares for at-the-market (ATM) sales.
- Prior ATM sales total $291,084,564 as of filing date; prior program terminated.
- Sales agents are Jefferies and Stifel; shares issuable under Sales Agreement dated Aug 2020 as amended.
- Registration statement automatically effective on Form S-3 filed Aug 2024.

## SEC filing metadata
- accession: 0001193125-26-082520
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000119312526082520/0001193125-26-082520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000119312526082520/xene-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-082520
- JSON: https://secwatch.observer/filing/0001193125-26-082520.json
- Plain text: https://secwatch.observer/filing/0001193125-26-082520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.